Sakuma Kaname, Tamura Ryuki, Hanyu Shintaro, Takahashi Haruka, Sato Hideaki, Oneyama Takahiro, Yamaguchi Akira, Tanaka Akira
Department of Oral and Maxillofacial Surgery, Niigata Hospital, The Nippon Dental University, Niigata, Niigata 951-8580, Japan.
Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Niigata 951-8580, Japan.
Mol Clin Oncol. 2017 Dec;7(6):1021-1026. doi: 10.3892/mco.2017.1459. Epub 2017 Oct 18.
Using trace three-dimensional culture, the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) can be tested even in cases with a small number of cells, including oral squamous cell carcinoma (OSCC), and evaluation of the antitumor effect with a drug concentration close to the level is possible. The present report aimed to evaluate the utility of the CD-DST in the assessment of the efficacy of single-agent and multidrug combination chemotherapy for OSCC in comparison with the clinical response rates and to examine the possible clinical application of CD-DST for such cases. A total of 33 OSCC patients from whom 33 samples were obtained from January 2010 to September 2015 were included. CD-DST was performed, individually and in combination, on the three drugs [i.e., cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (DOC)] and on super selective intra-arterial infusion chemoradiotherapy (IACRT). The overall evaluable rate of the CD-DST in OSCC was 81.8% (27 of 33 cases) and the sensitivity to each anticancer drug was evaluated. The efficacy rates of IACRT, cisplatin + 5-fluorouracil, and docetaxel + cisplatin + 5-fluorouracil (TPF) confirmed the estimated clinical response rates. In 14 of 33 patients, the results of CD-DST were compared with clinical efficacy, which was judged based on measurable lesions on imaging. For TPF therapy, the sensitivity test of the IACRT had a positive predictive value of 90.9% (10 of 11 cases) and a negative predictive value of 100% (3 of 3 cases); the accuracy of the susceptibility test for the anticancer agents was 92.8% (13 of 14 cases). The CD-DST may be useful in selecting multidrug combination chemotherapy and IACRT for OSCC, however, accumulation of further clinical data is required in the future.
采用微量三维培养法，即使在细胞数量较少的情况下，如口腔鳞状细胞癌（OSCC），也可以进行胶原凝胶微滴包埋培养药敏试验（CD-DST），并且能够以接近体内水平的药物浓度评估抗肿瘤效果。本报告旨在评估CD-DST在评估OSCC单药及多药联合化疗疗效方面的实用性，并与临床缓解率进行比较，同时探讨CD-DST在此类病例中的可能临床应用。纳入了2010年1月至2015年9月期间共33例OSCC患者，从中获取了33份样本。对三种药物[即顺铂（CDDP）、5-氟尿嘧啶（5-FU）和多西他赛（DOC）]以及超选择性动脉内灌注放化疗（IACRT）分别及联合进行了CD-DST。OSCC中CD-DST的总体可评估率为81.8%（33例中的27例），并评估了对每种抗癌药物的敏感性。IACRT、顺铂+5-氟尿嘧啶以及多西他赛+顺铂+5-氟尿嘧啶（TPF）的疗效证实了估计的临床缓解率。在33例患者中的14例中，将CD-DST结果与基于影像学上可测量病变判断的临床疗效进行了比较。对于TPF治疗，IACRT的敏感性试验阳性预测值为90.9%（11例中的10例），阴性预测值为100%（3例中的3例）；抗癌药物药敏试验的准确性为92.8%（14例中的13例）。CD-DST可能有助于为OSCC选择多药联合化疗和IACRT，然而，未来还需要积累更多的临床数据。
